Zacks: Brokerages Anticipate Cellectis S.A. (NASDAQ:CLLS) Will Announce Earnings of -$0.62 Per Share

Brokerages expect that Cellectis S.A. (NASDAQ:CLLS – Get Rating) will announce earnings of ($0.62) per share for the current quarter, Zacks reports. Two analysts have made estimates for Cellectis’ earnings, with estimates ranging from ($0.96) to ($0.30). Cellectis posted earnings of ($0.28) per share during the same quarter last year, which indicates a negative year over year growth rate of 121.4%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Cellectis will report full year earnings of ($2.37) per share for the current financial year, with EPS estimates ranging from ($3.80) to ($1.09). For the next year, analysts forecast that the firm will report earnings of ($1.32) per share, with EPS estimates ranging from ($1.61) to ($1.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Cellectis.

Cellectis (NASDAQ:CLLS – Get Rating) last posted its earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.50. Cellectis had a negative return on equity of 41.88% and a negative net margin of 170.26%. The company had revenue of $13.66 million for the quarter, compared to analysts’ expectations of $12.30 million. During the same period last year, the business posted ($0.95) earnings per share.

CLLS has been the topic of a number of recent analyst reports. Wells Fargo & Company cut shares of Cellectis from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $39.00 to $16.00 in a research note on Thursday, January 6th. StockNews.com cut shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Saturday, April 2nd. Finally, Zacks Investment Research lowered Cellectis from a “hold” rating to a “sell” rating in a report on Thursday, January 6th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $21.00.

Shares of NASDAQ CLLS opened at $4.13 on Friday. Cellectis has a fifty-two week low of $3.43 and a fifty-two week high of $20.42. The firm’s 50-day simple moving average is $4.52 and its 200 day simple moving average is $7.52. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.08. The stock has a market cap of $187.83 million, a P/E ratio of -1.63 and a beta of 2.25.

Large investors have recently added to or reduced their stakes in the stock. US Bancorp DE increased its stake in Cellectis by 94.0% in the 3rd quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,130 shares in the last quarter. Signaturefd LLC increased its stake in Cellectis by 1,066.0% in the 4th quarter. Signaturefd LLC now owns 3,801 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 3,475 shares in the last quarter. Advisor Group Holdings Inc. increased its stake in Cellectis by 73.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,950 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 2,103 shares in the last quarter. Deutsche Bank AG purchased a new position in Cellectis in the 3rd quarter worth about $42,000. Finally, Marshall Wace LLP purchased a new position in Cellectis in the 4th quarter worth about $44,000. 39.04% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Recommended Stories